<DOC>
	<DOCNO>NCT01582893</DOCNO>
	<brief_summary>Chronic dialysis patient end stage renal disease increase mortality rate compare age match healthy population . It know chronic inflammation contributes high incidence cardiovascular event chronic dialysis patient . Dialyzers make membrane increase pore size ( high cut-off Dialyzer HCO1100 ) may beneficial elimination inflammatory mediator may improve inflammatory status . Hypothesis : In study investigate whether treatment HCO1100 improve inflammatory status chronic dialysis patient .</brief_summary>
	<brief_title>Permeability Enhancement Reduce Chronic Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Dialysis treatment ≥ 3 month Dialysis 3x weekly Vascular access fistula CVC provide QB ≥ 250 ml/min Dialysis highflux dialyzer minimum 2 week begin study CRP &gt; 5mg/L least within 12 week inclusion Age &gt; 18 &lt; 99 Years Ability give write informed consent Missing informed consent form Clinically manifest infection current CRPvalue &gt; 50mg/L Serum albumin &lt; 35g/L Intake immune suppressive medication Pregnancy lactation Participation different study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>inflammation</keyword>
	<keyword>dialysis</keyword>
</DOC>